Rep. Dwight Evans Sells AbbVie Inc. (NYSE:ABBV) Stock

Representative Dwight Evans (D-Pennsylvania) recently sold shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on April 17th, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on April 3rd. The trade occurred in the Representative's "CETERA" account.

• 3 Biopharmaceutical Stocks Bucking the Sell-Off

Representative Dwight Evans also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Quanta Services NYSE: PWR on 4/3/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/3/2025.
• Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 4/3/2025.
• Sold $1,001 - $15,000 in shares of NextEra Energy NYSE: NEE on 4/3/2025.
• Sold $1,001 - $15,000 in shares of American Tower NYSE: AMT on 4/3/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 4/3/2025.
• Sold $1,001 - $15,000 in shares of ONEOK NYSE: OKE on 4/3/2025.
• Purchased $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 4/3/2025.
• Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 4/3/2025.
• Sold $1,001 - $15,000 in shares of Kinder Morgan NYSE: KMI on 4/3/2025.

AbbVie Trading Up 0.6 %

NYSE:ABBV opened at $172.78 on Friday. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $218.66. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The stock's 50 day simple moving average is $198.47 and its 200-day simple moving average is $187.82. The firm has a market cap of $305.64 billion, a P/E ratio of 71.99, a PEG ratio of 1.62 and a beta of 0.55.

• MarketBeat Week in Review – 03/24 - 03/28

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same quarter last year, the firm earned $2.79 earnings per share. Equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.80%. AbbVie's payout ratio is 273.33%.

Insider Activity at AbbVie

• AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

In related news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the completion of the transaction, the executive vice president now owns 53,234 shares of the company's stock, valued at approximately $11,183,398.72. This represents a 52.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 5,778 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $197.90, for a total value of $1,143,466.20. Following the sale, the executive vice president now owns 22,381 shares of the company's stock, valued at approximately $4,429,199.90. The trade was a 20.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 113,471 shares of company stock worth $23,426,451. 0.25% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AbbVie

Hedge funds have recently modified their holdings of the company. Mayfair Advisory Group LLC lifted its stake in shares of AbbVie by 16.3% during the first quarter. Mayfair Advisory Group LLC now owns 2,000 shares of the company's stock valued at $419,000 after buying an additional 280 shares during the period. Wolf Group Capital Advisors acquired a new position in AbbVie in the 1st quarter valued at $251,000. Shepherd Financial Partners LLC lifted its stake in shares of AbbVie by 1.9% during the 1st quarter. Shepherd Financial Partners LLC now owns 25,602 shares of the company's stock worth $5,364,000 after purchasing an additional 466 shares during the period. Clarius Group LLC boosted its holdings in shares of AbbVie by 26.5% during the first quarter. Clarius Group LLC now owns 20,148 shares of the company's stock worth $4,221,000 after purchasing an additional 4,218 shares during the last quarter. Finally, DHJJ Financial Advisors Ltd. grew its position in shares of AbbVie by 5.8% in the first quarter. DHJJ Financial Advisors Ltd. now owns 1,563 shares of the company's stock valued at $327,000 after purchasing an additional 86 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ABBV has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price objective on AbbVie from $210.00 to $240.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Raymond James reaffirmed an "outperform" rating and set a $220.00 price objective (up previously from $218.00) on shares of AbbVie in a report on Monday, February 3rd. Morgan Stanley reissued a "hold" rating on shares of AbbVie in a report on Friday, April 11th. Bank of America upped their price target on shares of AbbVie from $200.00 to $223.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 4th. Finally, UBS Group raised their price objective on shares of AbbVie from $181.00 to $190.00 and gave the company a "neutral" rating in a research note on Monday, February 3rd. Seven investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, AbbVie has an average rating of "Moderate Buy" and a consensus price target of $210.71.

View Our Latest Stock Analysis on ABBV

About Representative Evans

Dwight Evans (Democratic Party) is a member of the U.S. House, representing Pennsylvania's 3rd Congressional District. He assumed office on January 3, 2019. His current term ends on January 3, 2027. Evans (Democratic Party) is running for re-election to the U.S. House to represent Pennsylvania's 3rd Congressional District. He declared candidacy for the 2026 election. Evans earned his A.A. from the Community College of Philadelphia in 1973 and his bachelor's degree from La Salle College in 1975. He then attended Graduate Work at Temple University from 1975 to 1976. His professional experience includes working as an employment counselor/job developer for the Urban League of Philadelphia and as a teacher in the Philadelphia Public School System.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Featured Stories

• Five stocks we like better than AbbVie
• ETF Screener: Uses and Step-by-Step Guide
• 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
• About the Markup Calculator
• These 3 Stocks Have Huge Last 12 Months Shareholder Yields
• Consumer Staples Stocks, Explained
• Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here